Dual enzyme-driven redox homeostasis disruption with ultrasmall Pt-decorated MoS2 for combined ferroptosis therapy of hepatocellular carcinoma
Source abstract
Abstract
: There is an urgent clinical task for developing novel and precise therapies to enhance the treatment efficiency of hepatocellular carcinoma (HCC). Ferroptosis, a form of non-apoptotic regulated cell death, plays a significant role in improving cancer treatment outcomes. However, the robust antioxidant defense system within the tumor microenvironment (TME) severely impacts the ferroptosis efficacy. Nanozymes are emerging as promising candidates for inducing ferroptosis, but constructing novel nanozymes with high catalytic efficiency and multiple activities to amplify ferroptosis's therapeutic effects remains challenging. Here, we have judiciously fabricated a bimetallic nanozyme of ultrasmall Pt-decorated MoS 2 (Pt@MoS 2 ) through a simple and efficient aqueous synthesis strategy. The doping of ultrasmall Pt nanoparticles significantly enhances the photothermal activity, peroxidase-like activity, and glutathione oxidase-like activity of MoS 2 . Under the weak acidic conditions, over-expressed hydrogen peroxide (H 2 O 2 ), and high glutathione (GSH) levels, Pt@MoS 2 nanozyme with dual enzyme-driven redox homeostasis disruption can be activated to break down the antioxidant defense system and reshape the TME, effectively causing ·OH production from H 2 O 2 and GSH consumption. The dual nanozyme-remodulated TME suffers from oxidative cellular damage and significantly accelerates HCC apoptosis and ferroptosis. Both in vitro and in vivo experimental results demonstrate that Pt@MoS 2 has successfully induced cancer cell oxidative damage, lipid peroxidation, and downregulation of glutathione peroxidase 4 expression under near-infrared (NIR) laser-assisted photothermal therapy, exhibiting remarkable antitumor efficacy and good biosafety. This study offers insights into designing efficient bimetallic nanozymes for enhanced TME reshaping and ferroptosis therapy and expanding nanozymes' application in cancer treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (72)
Show source-provided references
1. A global view of hepatocellular carcinoma: trends, risk, prevention and management10.1038/s41575-019-0186-y ↗
2. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy10.1038/s41571-023-00825-3 ↗
3. LYRM2 promotes the growth and metastasis of hepatocellular carcinoma via enhancing HIF‐1α‐Dependent glucose metabolic reprogramming10.1111/jcmm.70241 ↗
4. Aberrant LYZ expression in tumor cells serves as the potential biomarker and target for HCC and promotes tumor progression via csGRP7810.1073/pnas.2215744120 ↗
5. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches10.1136/gutjnl-2014-307990 ↗
6. Medical therapies for hepatocellular carcinoma: a critical view of the evidence10.1038/nrgastro.2012.199 ↗
7. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma10.1038/s43018-022-00357-2 ↗
8. The liver cancer immune microenvironment: therapeutic implications for hepatocellular carcinoma10.1002/hep.32740 ↗
9. Tumor microenvironment ROS/pH cascade-responsive supramolecular nanoplatform with ROS regeneration property for enhanced hepatocellular carcinoma therapy10.1021/acsami.3c16022 ↗
10. Tumor microenvironment triggered cascade‐activation nanoplatform for synergistic and precise treatment of hepatocellular carcinoma10.1002/adhm.202002036 ↗
11. Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy10.1016/j.biomaterials.2021.121110 ↗
12. pH/GSH dual-responsive nanoparticle for auto-amplified tumor therapy of breast cancer10.1186/s12951-024-02588-0 ↗
13. Tumor microenvironment responsive nano-platform for overcoming sorafenib resistance of hepatocellular carcinoma
14. Targeted xCT‐mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the anti‐PD‐1/L1 response10.1002/advs.202203973 ↗
15. Ferroptosis‐enhanced immunotherapy with an injectable dextran‐chitosan hydrogel for the treatment of malignant ascites in hepatocellular carcinoma10.1002/advs.202300517 ↗
16. Nanoparticles synergize ferroptosis and cuproptosis to potentiate cancer immunotherapy
17. A nonferrous ferroptosis-like strategy for antioxidant inhibition–synergized nanocatalytic tumor therapeutics10.1126/sciadv.abj8833 ↗
18. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer10.1126/scitranslmed.adg3049 ↗
19. Recent progress in ferroptosis inducers for cancer therapy10.1002/adma.201904197 ↗
20. An ROS‐Activatable nanoassembly remodulates tumor cell metabolism for enhanced ferroptosis therapy10.1002/adhm.202101702 ↗
21. 2D catalytic nanozyme enables Cascade enzyodynamic effect‐boosted and Ca2+ overload‐induced synergistic ferroptosis/apoptosis in tumor
22. Starvation, ferroptosis, and prodrug therapy synergistically enabled by a cytochrome c oxidase like nanozyme10.1002/adma.202203236 ↗
23. Nanozyme-enabled analytical chemistry10.1021/acs.analchem.1c04492 ↗
24. Recent advances in nanozyme research10.1002/adma.201805368 ↗
25. Tang · 2021 · 75
26. Nanozyme‐enabled biomedical diagnosis: advances, trends, and challenges
27. Recent advances in nanozymes: from matters to bioapplications10.1002/adfm.202110432 ↗
28. A nanozyme with photo‐enhanced dual enzyme‐like activities for deep pancreatic cancer therapy10.1002/ange.201904751 ↗
29. Nanozyme-based cancer theranostics: a scientometric analysis and comprehensive review10.1016/j.nantod.2024.102386 ↗
30. Nanozymes: versatile platforms for cancer diagnosis and therapy10.1007/s40820-022-00828-2 ↗
31. Photothermally reinforced nanozyme remodeling tumor microenvironment of redox and metabolic homeostasis to enhance ferroptosis in tumor therapy10.1021/acsnano.4c13087 ↗
32. The applications of nanozymes in cancer therapy: based on regulating pyroptosis, ferroptosis and autophagy of tumor cells10.1039/D3NR01722B ↗
33. A molybdenum disulfide nanozyme with charge‐enhanced activity for ultrasound‐mediated cascade‐catalytic tumor ferroptosis
34. Metal-organic frameworks-based nanozymes for combined cancer therapy10.1016/j.nantod.2020.100920 ↗
35. Fe/Co bimetallic nanozyme disrupting tumorous self-regulatory pathways to potentiate ferroptosis
36. Microneedle patch integrated with porous silicon confined dual nanozymes for synergistic and hyperthermia‐enhanced nanocatalytic ferroptosis treatment of melanoma10.1002/adfm.202308183 ↗
37. Enzymatic degradation of plant biomass and synthetic polymers10.1038/s41570-020-0163-6 ↗
38. Nanozymes inspired by natural enzymes10.1021/accountsmr.1c00074 ↗
39. Harmonizing enzyme‐like cofactors to boost nanozyme catalysis10.1002/ange.202319108 ↗
40. Multienzyme‐like nanozymes: regulation, rational design, and application10.1002/adma.202211210 ↗
41. Bimetallic and multimetallic nanoparticles as nanozymes10.1016/j.snb.2021.129736 ↗
42. A nuclease-mimetic platinum nanozyme induces concurrent DNA platination and oxidative cleavage to overcome cancer drug resistance10.1038/s41467-022-35022-w ↗
43. Thermal atomization of platinum nanoparticles into single atoms: an effective strategy for engineering high-performance nanozymes10.1021/jacs.1c08581 ↗
44. Metrology of platinum nanozymes: mechanistic insights and analytical issues
45. A Pt1Pd single‐atom alloy nanozyme with boosted enzyme‐like activity for efficient photo‐mediated tumor therapy
46. Protective effects of Pt-NC single-atom nanozymes against myocardial ischemia-reperfusion injury10.1038/s41467-024-45927-3 ↗
47. Dual nanozyme-driven PtSn bimetallic nanoclusters for metal-enhanced tumor photothermal and catalytic therapy10.1021/acsnano.3c00423 ↗
48. Advances in bimetallic materials and bimetallic oxide nanozymes: synthesis, classification, catalytic mechanism and application in analytical chemistry
49. Synergistic surface ligand modification of Ni-Pt bimetallic nanozymes: enhanced catalytic activity and versatile detection of penicillin10.1016/j.snb.2024.136724 ↗
50. MoS2 based nanomaterials: advanced antibacterial agents for future10.1016/j.jconrel.2022.05.047 ↗
51. Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics10.1186/s12951-024-02785-x ↗
52. 2D Van der Waals heterostructures for chemical sensing10.1002/adfm.202207065 ↗
53. Tissue imprinting on 2D nanoflakes-capped silicon nanowires for lipidomic mass spectrometry imaging and cancer diagnosis10.1021/acsnano.2c02616 ↗
54. Highly dispersed Pt nanoparticles on 2D MoS2 nanosheets for efficient and stable hydrogen evolution reaction10.1039/D1TA10725A ↗
55. NIR-II-enhanced Pt-MoS2 nanozymes for synergistic photothermal and chemodynamic therapy against methicillin-resistant Staphylococcus aureus to promote wound healing10.26599/NR.2025.94907538 ↗
56. MoS2 nanoflower supported Pt nanoparticle as an efficient electrocatalyst for ethanol oxidation reaction10.1016/j.ijhydene.2019.04.251 ↗
57. A simple Ag–MoS2 hybrid nanozyme-based sensor array for colorimetric identification of biothiols and cancer cells10.1039/D4RA05409A ↗
58. Architecturally designed Pt–MoS 2 and Pt–graphene composites for electrocatalytic methanol oxidation10.1039/C5CP04141D ↗
59. Phase-dependent growth of Pt on MoS2 for highly efficient H2 evolution10.1038/s41586-023-06339-3 ↗
60. Two‐dimensional nanomaterials for photothermal therapy10.1002/ange.201911477 ↗
61. Photothermal therapy10.1016/j.jconrel.2020.06.032 ↗
62. Tumor response and NIR‐II photonic thermal co‐enhanced catalytic therapy based on single‐atom manganese nanozyme10.1002/adfm.202206157 ↗
63. Turning silica into enzymes by hydrogenation: simultaneously achieving oxygen vacancy engineering and tumor adaptive accumulation for NIR‐II‐Potentiated therapy10.1002/adfm.202306392 ↗
64. Ye · 2025
65. Targeted delivery of active sites by oxygen vacancy-engineered bimetal silicate nanozymes for intratumoral aggregation-potentiated catalytic therapy10.1021/acsnano.3c08780 ↗
66. Plasma-assisted controllable doping of nitrogen into MoS2 nanosheets as efficient nanozymes with enhanced peroxidase-like catalysis activity10.1021/acsami.0c01789 ↗
67. Ligand phase Separation-Promoted,“Squeezing-Out” mode explaining the mechanism and implications of neutral nanoparticles that escaped from lysosomes10.1021/acsnano.3c09452 ↗
68. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability10.1016/j.biomaterials.2010.06.024 ↗
69. “Resource-Conserving” engineered nanoparticles mediate disulfidptosis by overcoming resistance to ferroptosis for antitumor immunotherapy10.1016/j.cej.2024.157409 ↗
70. Organelle synergy unleashed: modulating mitochondrial-endoplasmic reticulum contacts with a self-assembled prodrug amplifies ferroptosis for innovative cancer therapy10.1016/j.cej.2024.153364 ↗
71. Cancer cell membrane biomimetic mesoporous silica nanotheranostics for enhanced Ferroptosis-mediated immuogenic cell death on gastric cancer10.1016/j.cej.2022.140868 ↗
72. A co-delivery platform for synergistic promotion of angiogenesis based on biodegradable, therapeutic and self-reporting luminescent porous silicon microparticles10.1016/j.biomaterials.2021.120772 ↗